Reservoirs and Eradication
- Galit Alter, PhD: Innate immune responses to chronic viral infections
- Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
- Rajesh Gandhi, MD: Studies of HIV reservoirs and immune-based therapies, including clinical trials
- Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
- Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
- Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
- Jonathan Li, MD: HIV drug resistance, persistence, and cure
- Mathias Lichterfeld, MD, PhD: HIV immune defense mechanisms and clinical development of HIV eradication/cure strategies
- Eric Rosenberg, MD: Mechanisms of successful cellular immune responses to HIV
- Athe Tsibris, MD: HIV reservoirs and cure
Vaccines
- Galit Alter, PhD: Innate immune responses to chronic viral infections
- Lindsey Baden, MD: Vaccines and infectious complications of immunosuppression
- Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
- Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
- Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
- Bruce Walker, MD: Cellular Mechanisms of HIV Control
Resistance and Clinical Trials
- Lindsey Baden, MD: Vaccines and infectious complications of immunosuppression
- Scott Dryden-Peterson, MD, MSc: Programmatic and implementation trials in HIV and cancer care; HIV treatment and prevention clinical trials (ACTG, IMPAACT, HPTN); Cervical cancer prevention trials (CASCADE)
- Rajesh Gandhi, MD: Studies of HIV reservoirs and immune-based therapies, including clinical trials
- Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
- Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
- Jonathan Li, MD: HIV drug resistance, persistence, and cure
- Mathias Lichterfeld, MD, PhD: HIV immune defense mechanisms and clinical development of HIV eradication/cure strategies
- Shahin Lockman, MD: HIV in developing countries
- Gregory Robbins, MD, MPH: Clinical decision support systems to improve HIV health outcomes
- Paul Sax, MD: Clinical trials and cost-effectiveness of HIV therapy
- Bruce Walker, MD: Cellular Mechanisms of HIV Control
Adherence
International
- Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
- Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
- Andrea Ciaranello, MD: Strategies to improve the care of HIV-infected women, children, and adolescents
- Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
- Scott Dryden-Peterson, MD, MSc: Effect of HIV on cancer risk and oncologic outcomes; Programmatic and implementation trials in HIV and cancer care; HIV treatment and prevention clinical trials (ACTG, IMPAACT, HPTN); Cervical cancer prevention trials (CASCADE)
- Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
- Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
- Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
- Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
- Jonathan Li, MD, MMSc: HIV and SARS-CoV-2 drug resistance, persistence, and cure
- Shahin Lockman, MD: HIV in developing countries
- Anne Neilan, MD MPH: Epidemiology, health policy, and simulation modeling among adolescents and young adults living with and at risk of HIV
- Mark Siedner, MD: Improving health and quality of life for people with HIV in sub-Saharan Africa
- Bruce Walker, MD: Cellular Mechanisms of HIV Control
Modeling and Outcomes
- Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
- Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
- Andrea Ciaranello, MD: Strategies to improve the care of HIV-infected women, children, and adolescents
- Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
- Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
- Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
- Anne Neilan, MD MPH: Epidemiology, health policy, and simulation modeling among adolescents and young adults living with and at risk of HIV
- Paul Sax, MD: Clinical trials and cost-effectiveness of HIV therapy
- Virginia Triant, MD, MPH: Outcomes research on non-communicable/aging-related diseases and HIV